
													
															
															Year
															DEALS // DEV.
															Country
															
															Therapeutic Area
															Study Phase
															Deal Type
															Product Type
															Dosage Form
															Lead Product
															Target

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : COR-1004
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Corsera Health Files Phase 1 Trial for Preventive RNAi Medicine in Cardiovascular Disease
Details : COR-1004, an oligonucleotide targeting PCSK9, shows promise in reducing high LDL cholesterol levels, a key focus area in cardiovascular health.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
October 27, 2025
Lead Product(s) : COR-1004
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
